Sterling Capital Management LLC reduced its stake in MEDNAX Inc (NYSE:MD) by 89.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 42,471 shares of the company’s stock after selling 350,220 shares during the period. Sterling Capital Management LLC’s holdings in MEDNAX were worth $1,838,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds also recently added to or reduced their stakes in the company. Blair William & Co. IL bought a new stake in MEDNAX during the 1st quarter worth approximately $211,000. Point72 Hong Kong Ltd bought a new stake in MEDNAX during the 2nd quarter worth approximately $172,000. C M Bidwell & Associates Ltd. bought a new stake in MEDNAX during the 1st quarter worth approximately $278,000. Asset Management One Co. Ltd. bought a new stake in MEDNAX during the 1st quarter worth approximately $281,000. Finally, NumerixS Investment Technologies Inc grew its position in MEDNAX by 147.8% during the 2nd quarter. NumerixS Investment Technologies Inc now owns 5,700 shares of the company’s stock worth $247,000 after acquiring an additional 3,400 shares during the last quarter. Institutional investors own 95.50% of the company’s stock.
NYSE:MD opened at $46.41 on Tuesday. MEDNAX Inc has a 52-week low of $40.56 and a 52-week high of $63.04. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.52 and a current ratio of 1.52. The firm has a market cap of $4.36 billion, a price-to-earnings ratio of 14.63, a PEG ratio of 1.28 and a beta of 0.23.
A number of research firms recently commented on MD. Zacks Investment Research lowered MEDNAX from a “hold” rating to a “sell” rating in a research report on Friday, July 20th. Leerink Swann began coverage on MEDNAX in a research report on Thursday, July 12th. They set a “market perform” rating and a $50.00 price target on the stock. Bank of America upgraded MEDNAX from an “underperform” rating to a “neutral” rating and decreased their price target for the stock from $60.00 to $50.00 in a research report on Tuesday, September 18th. Stifel Nicolaus set a $47.00 price target on MEDNAX and gave the stock a “hold” rating in a research report on Thursday, August 2nd. Finally, Credit Suisse Group upgraded MEDNAX from a “neutral” rating to an “outperform” rating and increased their price target for the stock from $47.00 to $55.00 in a research report on Friday, August 3rd. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and five have assigned a buy rating to the company. MEDNAX presently has an average rating of “Hold” and a consensus target price of $54.40.
In other MEDNAX news, insider John C. Pepia sold 3,500 shares of the company’s stock in a transaction on Tuesday, August 14th. The stock was sold at an average price of $48.18, for a total transaction of $168,630.00. Following the transaction, the insider now owns 30,148 shares of the company’s stock, valued at approximately $1,452,530.64. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 2.70% of the stock is currently owned by corporate insiders.
MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.
Featured Story: Insider Trading
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.